ការប្រឆាំងនឹងអេជស៊ីអេចដោយផ្ទាល់អាចកាត់បន្ថយហានិភ័យនៃជំងឺមហារីកថ្លើម

At the 2017 annual meeting of the American Liver Disease Association, a large observational study reported that the use of direct antiviral (DAA) therapy to eradicate hepatitis C virus (HCV) can reduce the risk of liver cancer by 71%. In patients with cirrhosis and non-cirrhosis, the risk of liver cancer is reduced. In the United States, most primary liver cancer occurs in people infected with HCV. Researchers at the University of Washington hypothesized that the eradication of HCV could eliminate or at least significantly reduce the risk of មហារីកថ្លើម. However, before HCV eradication, the patient may have developed cirrhosis or liver fibrosis. Even if HCV eradication may be too late, there is still a risk of developing liver cancer. In addition, recent studies suggest that the risk of liver cancer in HCV-infected patients who have received new DAA treatment is still increased. The researchers analyzed 62,051 patients with HCV infection who received 83,695 antiviral treatments. After 180 days of antiviral treatment, an average of 3,271 new liver cancers occurred during a follow-up of 6.1 years. Patients with cirrhosis who failed treatment had the highest incidence of liver cancer (3.25 / 100 person-years), followed by patients with cirrhosis who had sustained virological response (SVR) (1.97 / 100 person-years), and patients who had no cirrhosis but failed treatment (0.87 / 100 person-years) and patients without cirrhosis who obtained SVR (0.24 / 100 person-years). Multivariate analysis showed that after adjusting for potential confounders, SVR was significantly associated with a lower risk of liver cancer, regardless of whether DAA treatment (aHR = 0.29), DAA combined with interferon treatment (aHR = 0.48), or interferon only treatment (aHR = 0.32). 

អ្នកស្រាវជ្រាវបានសង្កត់ធ្ងន់ថា ការសិក្សាមួយនៅឯសភាជំងឺថ្លើមអឺរ៉ុបកាលពីឆ្នាំមុនបានបង្ហាញថាអ្នកជំងឺ HCV ដែលត្រូវបានព្យាបាលដោយ DAA ហាក់ដូចជាមានអត្រានៃការកើតឡើងវិញនៃជំងឺមហារីកថ្លើមខ្ពស់ជាង។ លទ្ធផល​នេះ​មាន​ភាពចម្រូងចម្រាស​ខ្លាំង​ព្រោះ​ទំនាក់ទំនង​រវាង HCV និង​មហារីក​ថ្លើម​ផ្តល់​យោបល់​ថា​ការ​លុបបំបាត់​មេរោគ HCV គួរតែ​កាត់បន្ថយ​ហានិភ័យ​នៃ​ជំងឺមហារីក​ថ្លើម​មិនមែន​ដើម្បី​បង្កើន​ហានិភ័យ​នៃ​ជំងឺមហារីក​ថ្លើម​នោះទេ។ ការសន្និដ្ឋាននៃការសិក្សាអង្កេតនេះគឺប្រាកដណាស់ថាការលុបបំបាត់ DAA នៃ HCV អាចកាត់បន្ថយហានិភ័យនៃជំងឺមហារីកថ្លើមបាន 71% ដែលបង្ហាញថាមិនចាំបាច់ព្រួយបារម្ភអំពីការលុបបំបាត់ HCV ដើម្បីបង្កើនហានិភ័យនៃជំងឺមហារីកថ្លើមនោះទេ។ ការលុបបំបាត់ HCV គឺដើម្បីកាត់បន្ថយហានិភ័យនៃជំងឺមហារីកថ្លើម។